BRPI0913940A2 - formulação de fenofibrato com biodisponibilidade oral aumentada - Google Patents
formulação de fenofibrato com biodisponibilidade oral aumentadaInfo
- Publication number
- BRPI0913940A2 BRPI0913940A2 BRPI0913940A BRPI0913940A BRPI0913940A2 BR PI0913940 A2 BRPI0913940 A2 BR PI0913940A2 BR PI0913940 A BRPI0913940 A BR PI0913940A BR PI0913940 A BRPI0913940 A BR PI0913940A BR PI0913940 A2 BRPI0913940 A2 BR PI0913940A2
- Authority
- BR
- Brazil
- Prior art keywords
- oral bioavailability
- increased oral
- fenofibrate formulation
- fenofibrate
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1384MU2008 | 2008-07-03 | ||
| PCT/IN2009/000365 WO2010082214A2 (en) | 2008-07-03 | 2009-06-26 | Fenofibrate formulation with enhanced oral bioavailability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0913940A2 true BRPI0913940A2 (pt) | 2015-10-20 |
Family
ID=42340174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0913940A BRPI0913940A2 (pt) | 2008-07-03 | 2009-06-26 | formulação de fenofibrato com biodisponibilidade oral aumentada |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110160274A1 (pt) |
| EP (1) | EP2306989A2 (pt) |
| JP (1) | JP2011526621A (pt) |
| KR (1) | KR20110027778A (pt) |
| CN (1) | CN102083422A (pt) |
| AR (1) | AR072795A1 (pt) |
| AU (1) | AU2009337465A1 (pt) |
| BR (1) | BRPI0913940A2 (pt) |
| CA (1) | CA2729262A1 (pt) |
| MX (1) | MX2010014200A (pt) |
| RU (1) | RU2011103066A (pt) |
| WO (1) | WO2010082214A2 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102247598A (zh) * | 2011-06-13 | 2011-11-23 | 浙江爱生药业有限公司 | 油溶性药物组合物 |
| WO2013064853A1 (en) | 2011-11-05 | 2013-05-10 | Lupin Atlantis Holdings, S.A. | Reduced dose oral pharmaceutical compositions of fenofibrate |
| WO2014091318A1 (en) | 2012-12-11 | 2014-06-19 | Lupin Atlantis Holdings, S.A. | Reduced dose pharmaceutical compositions of fenofibrate |
| CA3191478A1 (en) | 2020-09-29 | 2022-04-07 | Paola Yazmin Ollervides Rubio | Pharmaceutical combinations of statins and fibrates for the treatment and prevention of hyperlipidemias and cardiovascular disease |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545628A (en) * | 1995-01-10 | 1996-08-13 | Galephar P.R. Inc. | Pharmaceutical composition containing fenofibrate |
| FR2737121B1 (fr) * | 1995-07-27 | 1997-10-03 | Cl Pharma | Nouvelles formulations galeniques du fenofibrate et leurs applications |
| US6814977B1 (en) * | 1998-12-18 | 2004-11-09 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6719999B2 (en) * | 1999-03-31 | 2004-04-13 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
| US6982281B1 (en) * | 2000-11-17 | 2006-01-03 | Lipocine Inc | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| FR2803203B1 (fr) * | 1999-12-31 | 2002-05-10 | Fournier Ind & Sante | Nouvelles formulations galeniques du fenofibrate |
| EP1539117A4 (en) * | 2002-06-28 | 2005-12-14 | Shire Lab Inc | FORMULATIONS BASED ON FENOFIBRATE AND / OR FENOFIBRATE DERIVATIVES HAVING IMPROVED ORAL BIOAVAILABILITY |
| US20040005339A1 (en) * | 2002-06-28 | 2004-01-08 | Shojaei Amir H. | Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability |
| US9173847B2 (en) * | 2003-10-10 | 2015-11-03 | Veloxis Pharmaceuticals A/S | Tablet comprising a fibrate |
-
2009
- 2009-06-26 RU RU2011103066/15A patent/RU2011103066A/ru not_active Application Discontinuation
- 2009-06-26 US US13/002,372 patent/US20110160274A1/en not_active Abandoned
- 2009-06-26 BR BRPI0913940A patent/BRPI0913940A2/pt not_active IP Right Cessation
- 2009-06-26 CA CA2729262A patent/CA2729262A1/en not_active Abandoned
- 2009-06-26 EP EP09838194A patent/EP2306989A2/en not_active Withdrawn
- 2009-06-26 MX MX2010014200A patent/MX2010014200A/es not_active Application Discontinuation
- 2009-06-26 KR KR1020117000785A patent/KR20110027778A/ko not_active Application Discontinuation
- 2009-06-26 CN CN2009801259631A patent/CN102083422A/zh active Pending
- 2009-06-26 JP JP2011515736A patent/JP2011526621A/ja not_active Withdrawn
- 2009-06-26 AU AU2009337465A patent/AU2009337465A1/en not_active Abandoned
- 2009-06-26 WO PCT/IN2009/000365 patent/WO2010082214A2/en active Application Filing
- 2009-07-03 AR ARP090102515A patent/AR072795A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010014200A (es) | 2011-03-21 |
| WO2010082214A2 (en) | 2010-07-22 |
| WO2010082214A3 (en) | 2010-10-28 |
| AR072795A1 (es) | 2010-09-22 |
| RU2011103066A (ru) | 2012-08-10 |
| KR20110027778A (ko) | 2011-03-16 |
| JP2011526621A (ja) | 2011-10-13 |
| EP2306989A2 (en) | 2011-04-13 |
| CA2729262A1 (en) | 2010-07-22 |
| CN102083422A (zh) | 2011-06-01 |
| AU2009337465A1 (en) | 2010-07-22 |
| US20110160274A1 (en) | 2011-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2018030I2 (el) | Φαρμακοτεχνικη μορφη 514 | |
| BRPI0920521A2 (pt) | combinação farmacêutica | |
| BRPI0820381A2 (pt) | Formulações farmacêuticas | |
| BRPI0912271A2 (pt) | co-autoria estruturada | |
| DK2073795T3 (da) | Misbrugssikret lægemiddelformulation | |
| DK2264676T3 (da) | Sensor | |
| SMT201400069B (it) | Formulazione farmaceutica | |
| NO20083238L (no) | Narresmokk | |
| BRPI0921654A2 (pt) | formulação farmacêutica | |
| BRPI0814188A2 (pt) | Formulações | |
| DK2285413T3 (da) | Farmaceutisk sammensætning | |
| BRPI0921038A2 (pt) | ácido naftilacéticos | |
| BRPI1009465A2 (pt) | Formulação | |
| BRPI0921313A2 (pt) | composição farmaucêutica | |
| DK2271618T3 (da) | Farmaceutiske forbindelser | |
| BRPI0912171A2 (pt) | composição farmacêutica | |
| BRPI0908455A2 (pt) | formulações de flibanserina | |
| BRPI0912656A2 (pt) | formulação farmacêutica sólida | |
| DK2323933T3 (da) | Stableenhed | |
| DK2271321T3 (da) | Farmaceutisk sammensætning 271 | |
| FI20080348A0 (fi) | Uudenlainen farmaseuttinen formulaatio | |
| BRPI0913940A2 (pt) | formulação de fenofibrato com biodisponibilidade oral aumentada | |
| BRPI0920833A2 (pt) | preparação de benzonorborbenos | |
| BRPI0823402A2 (pt) | Formulações farmacêuticas de olmesartan | |
| BRPI0913709A2 (pt) | "formulação farmacêutica" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 3A, 4A, 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |